title: Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
abstract: OBJECTIVE
  Acetylation of histones by histone acetyl transferases (HATs) leads to transcriptional activation, while histone deacetylase (HDAC) activity leads to transcriptional repression. Abnormalities of histone acetylation are associated with the malignant phenotype. Depsipeptide (FR901228) inhibits HDAC and has shown anticancer activity in preclinical models. We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of depsipeptide in a nonhuman primate model that is highly predictive of human CSF penetration.
  
  
  METHODS
  Depsipeptide was administered intravenously at a dose of 10 mg/m(2) over 4 h to three different animals. Serial blood samples were obtained from all animals and serial CSF samples were obtained from two animals. Plasma and CSF concentrations of depsipeptide were measured using liquid chromatography/tandem mass spectrometry. Concentration-versus-time data were modeled using model-independent and model-dependent methods.
  
  
  RESULTS
  The peak plasma concentration (median+/-SD) was 245+/-50 n M and occurred within the first 2 h of the infusion. The terminal half-life was 205+/-315 min, the AUC extrapolated to infinity was 50+/-15 micro M.min, and the total body clearance was 350+/-65 ml/min/m(2). In the two animals that had CSF sampling performed, the CSF peak concentration was 3.6 n M in one animal and 2.3 n M in the other, and the CSF half-lives were 250 and 325 min. The CSF penetration of depsipeptide (AUC(CSF):AUC(plasma)) was 2% in each animal. Observed changes included anorexia, fatigue, elevation of creatine phosphokinase (CPK) enzyme levels (muscle fraction), and transient early leukopenia. All animals recovered without sequelae.
  
  
  CONCLUSIONS
  Although the CSF exposure to depsipeptide after intravenous administration was only 2%, CSF concentrations approached the IC(50) of depsipeptide in vitro for some tumors. Systemic administration of this agent may be useful for the treatment of leptomeningeal tumors.
authors.affiliation: Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. sberg@txccc.org
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Berg
authors.forename: Jeffery
authors.initials: J
authors.lastname: Stone
authors.forename: Jim J
authors.initials: JJ
authors.lastname: Xiao
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Chan
authors.forename: Jed
authors.initials: J
authors.lastname: Nuchtern
authors.forename: Robert
authors.initials: R
authors.lastname: Dauser
authors.forename: Leticia
authors.initials: L
authors.lastname: McGuffey
authors.forename: Patrick
authors.initials: P
authors.lastname: Thompson
authors.forename: Susan M
authors.initials: SM
authors.lastname: Blaney
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D002555:Cerebrospinal Fluid / Q000737:chemistry; D047630:Depsipeptides; D004305:Dose-Response Relationship, Drug; D007262:Infusions, Intravenous; D008253:Macaca mulatta; D008297:Male; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D000903:Antibiotics, Antineoplastic; D047630:Depsipeptides; D010456:Peptides, Cyclic; C087123:romidepsin